Back grey_arrow_rt.gif
 
Archived NATAP Articles from October 2001
 
null.gif
 
 
  1. Clinical data on the new extended release formulation of d4T  - (ECCATHI), Athens, Greece
    (10/31/01)

    2.  
  2. 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV  - Index Page - (Lipodystrophy Conf) Athens, Greece
    (10/31/01)

    3.  
  3. Abnormalities of Glucose Metabolism, Including Insulin Resistance
    (10/31/01)

    4.  
  4. Risk for Increased Heart Disease in 45-Year Old Women with HIV and Lipodystrophy
    (10/31/01)

    5.  
  5. Pre-Conference Overview  - (Lipodystrophy Conf) Athens, Greece
    (10/31/01)

    6.  
  6. Lipodystrophy, Protease Inhibitors, and Insulin Resistance   - Day 1 - (Lipodystrophy Conf) Athens, Greece
    (10/22/01)

    7.  
  7. Amprenavir and Effects on Metabolics & Lipoatrophy   - Day 2 - (Lipodystrophy Conf) Athens, Greece
    (10/22/01)

    8.  
  8. Bulletted Highlights From Lipodystrophy and Adverse Drug Reactions in HIV Workshop   - Day 3 - (Lipodystrophy Conf) Athens, Greece
    (10/22/01)

    9.  
  9. Abacavir: Fat Redistribution, and Changes in Cholesterol & Triglycerides   - Report - (Lipodystrophy Conf) Athens, Greece
    (10/22/01)

    10.  
  10. Mitochondrial Toxicity and Lipodystrophy   - Report - (Lipodystrophy Conf) Athens, Greece
    (10/21/01)

    11.  
  11. Nevaripine: lipids and heart disease; hepatotoxicity and a role for therapeutic drug monitoring   - Report - (Lipodystrophy Conf) Athens, Greece
    (10/21/01)

    12.  
  12. High prevalence of Thyroid Abnormalities in the era of HAART   - Report - (Lipodystrophy Conf) Athens, Greece
    (10/21/01)

    13.  
  13. Report on Lactic Acidosis and other Mitochondrial Toxicity Issues   - Report - (Lipodystrophy Conf) Athens, Greece
    (10/20/01)

    14.  
  14. Report on Possible Therapy for Lipodystrophy   - Report - (Lipodystrophy Conf) Athens, Greece
    (10/20/01)

    15.  
  15. Unrecognized fructose intolerance often underlies unexplained GI symptoms
    (10/20/01)

    16.  
  16. Nerve Growth Factor Improves HIV-Associated Sensory Neuropathy
    (10/18/01)

    17.  
  17. Preventable Factors Linked to Indinavir-Associated Renal Complications
    (10/18/01)

    18.  
  18. On-site healthcare improves compliance by HIV-infected female drug users
    (10/18/01)

    19.  
  19. Unique posterior keratopathy seen in HIV-infected men
    (10/18/01)

    20.  
  20. Older HIV patients have greater PCP mortality
    (10/17/01)

    21.  
  21. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
    (10/17/01)

    22.  
  22. Federal Funding for HIV / AIDS
    (10/17/01)

    23.  
  23. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users
    (10/17/01)

    24.  
  24. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study
    (10/15/01)

    25.  
  25. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents
    (10/15/01)

    26.  
  26. University of Pittsburgh Receives $7.7 Million to Lead a Study on Racially Based Differences in Response to Hepatitis C Therapy
    (10/15/01)

    27.  
  27. NATAP REPORTS: Current Review & Update on Hepatitis C & HIV/HCV Coinfection PDF More On PMPA...
    (10/13/2001)

    28.  
  28. FDA Advisory Committee Recommends PMPA Approval For Treatment-Experienced
    (10/13/2001)

    29.  
  29. Treatment of Acute Hepatitis C with Interferon Alfa-2b
    (10/13/2001)

    30.  
  30. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
    (10/12/2001)

    31.  
  31. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C
    (10/12/2001)

    32.  
  32. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers
    (10/12/2001)

    33.  
  33. Screening for Anal and Cervical Dysplasia in HIV-Infected Patients PDF
    (10/11/2001)

    34.  
  34. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up
    (10/11/2001)

    35.  
  35. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200
    (10/11/2001)

    36.  
  36. Discontinuation of primary Pneumocystis carinii prophylaxis after reconstitution of CD4 cell counts in HIV-infected children

    37.  
  37. FDA Grants Market Clearance of Visible Genetics' HIV Genotyping System
    (10/10/2001)

    38.  
  38. Kaletra Report
    (10/10/2001)

    39.  
  39. Does HAART Affect Liver Disease Progression in HCV/HIV Coinfected Patients?
    (10/10/2001)

    40.  
  40. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices PDF
    (10/09/2001)

    41.  
  41. Factors Affecting Liver Fibrosis in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Patients: Impact of Protease Inhibitor Therapy
    (10/09/2001)

    42.  
  42. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    (10/09/2001)

    43.  
  43. Breastfeeding & HCV Transmission
    (10/08/2001)

    44.  
  44. STI rise in UK could herald HIV upsurge
    (10/07/2001)

    45.  
  45. Anthrax & Smallpox Vaccines: terrorist attacks
    (10/02/2001)

    46.